The Immunology Market encompasses a broad range of therapies, diagnostic technologies, applications, and end users. According to Market Research Future, the market is projected to increase from USD 116.4 billion in 2025 to USD 220.18 billion by 2035 at a CAGR of 6.58%.

The market is segmented by immunotherapy type, application, target type, end user, test type, and region. Immunotherapy types include checkpoint inhibitors, adoptive cell therapy, oncolytic viruses, cancer vaccines, and immunomodulators. Applications include cancer, autoimmune diseases, infectious diseases, neurological disorders, and allergic diseases.

By target type, the market includes antibody-based therapies, cell-based therapies, gene therapies, small molecule therapies, and peptides. Hospitals represent a major end-user category, while pharmaceutical and biotechnology companies contribute significantly through research, drug development, and commercialization.

Flow cytometry represents an important testing technology, alongside ELISA, Western blotting, immunohistochemistry, and immunofluorescence. These technologies support disease research, diagnosis, treatment monitoring, and clinical development.

Major companies identified by Market Research Future include AbbVie, Roche, Johnson & Johnson, Merck & Co., Amgen, Gilead Sciences, Sanofi, Bristol-Myers Squibb, and Novartis.

Competition is driven by product innovation, clinical research, strategic collaborations, and investment in personalized medicine. As demand for targeted therapies increases, companies with strong research pipelines and advanced technologies are positioned to capture emerging opportunities.

Discover emerging opportunities with in-depth research reports:

Artificial Insemination Market Share

Transient Ischemic Attack Market Trends

Radioimmunoassay Market Growth

Capsule Market Demand

Homeopathy Market Volume